Camille Bedrosian

Board Member

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

Affiliation history

Recorded current and former roles; source labels appear when available.

Recorded roles and earnings-call appearances connecting this person to public companies.

AMLX

Current role

Board Member

2023-01-01–present

1 call Latest call 2026-03-03

CRNX

Current role

Board Member

RARE

Current role

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year	Company	Role	Salary	Bonus	Stock awards	Option awards	Incentive	Other	Total
2025	Amylyx Pharmaceuticals, Inc. (AMLX)	Chief Medical Officer	$575,000	—	$246,996	$312,872	$275,569	$157,237	$1,567,674
2023	Amylyx Pharmaceuticals, Inc. (AMLX)	Chief Medical Officer	$56,763	$173,000	$754,246	$1,386,012	—	$2,838	$2,372,859
2022	Ultragenyx Pharmaceutical Inc. (RARE)	Chief Medical Officer and Executive Vice President	$596,000	—	$2,007,768	$892,550	$246,750	$12,200	$3,755,268
2021	Ultragenyx Pharmaceutical Inc. (RARE)	Chief Medical Officer and Executive Vice President	$567,123	—	$1,653,212	$866,427	$249,260	$8,700	$3,344,722
2020	Ultragenyx Pharmaceutical Inc. (RARE)	Chief Medical Officer and Executive Vice President	$546,686	—	$695,392	$674,871	$297,731	—	$2,214,680
2019	Ultragenyx Pharmaceutical Inc. (RARE)	Chief Medical Officer and Executive Vice President	$511,186	—	$878,150	$863,513	$230,076	$2,729	$2,485,654
2018	Ultragenyx Pharmaceutical Inc. (RARE)	Chief Medical Officer and Executive Vice President	$442,308	$210,000	$990,000	$2,906,983	$189,274	$107,727	$4,846,292

Earnings-call appearances and filed executive appointments or departures, newest first.